Summary:
If you decide to take part in this study you will receive either liraglutide or an inactive drug
(placebo). Placebo is identical in appearance to the active drug but contains no active ingredient.
For this study the term “study drug” refers to both liraglutide and placebo.
This study will assess the effect of a liraglutide-induced weight loss on obstructive sleep apnea.
This study is part of an international program and is planned to take place in Canada and the U.S.
It will include approximately 308 men and women 18 – 64 years of age.
Qualified Participants Must:
• Be 18-64 years of age
•
Suffer from sleep apnea
Qualified Participants May Receive:
You may receive compensation for office visits.